Summary
Global Markets Direct’s, ‘Acinetobacter Infections - Pipeline Review, H1 2016’, provides an overview of the Acinetobacter Infections pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acinetobacter Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acinetobacter Infections and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acinetobacter Infections
- The report reviews pipeline therapeutics for Acinetobacter Infections by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acinetobacter Infections therapeutics and enlists all their major and minor projects
- The report assesses Acinetobacter Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acinetobacter Infections
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acinetobacter Infections
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acinetobacter Infections pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Achaogen Inc.
Adenium Biotech ApS
AmpliPhi Biosciences Corporation
Aridis Pharmaceuticals LLC
AstraZeneca Plc
AvidBiotics Corp.
Cellceutix Corporation
Emergent BioSolutions Inc.
Evaxion Biotech ApS
F. Hoffmann-La Roche Ltd.
FOB Synthesis, Inc.
LegoChem Biosciences, Inc
Melinta Therapeutics, Inc
MicuRx Pharmaceuticals, Inc.
Nosopharm SAS
Omnia Molecular Ltd.
Pfizer Inc.
Phylogica Limited
Sarepta Therapeutics, Inc.
Sealife PHARMA GMBH
Shionogi & Co., Ltd.
Techulon, Inc.
Tetraphase Pharmaceuticals Inc.
Varinel, Inc.
Vaxdyn, S.L.
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Acinetobacter Infections Overview 8
Therapeutics Development 9
Pipeline Products for Acinetobacter Infections – Overview 9
Pipeline Products for Acinetobacter Infections – Comparative Analysis 10
Acinetobacter Infections – Therapeutics under Development by Companies 11
Acinetobacter Infections – Therapeutics under Investigation by Universities/Institutes 13
Acinetobacter Infections – Pipeline Products Glance 14
Late Stage Products 14
Early Stage Products 15
Acinetobacter Infections – Products under Development by Companies 16
Acinetobacter Infections – Products under Investigation by Universities/Institutes 19
Acinetobacter Infections – Companies Involved in Therapeutics Development 20
Achaogen Inc. 20
Adenium Biotech ApS 21
AmpliPhi Biosciences Corporation 22
Aridis Pharmaceuticals LLC 23
AstraZeneca Plc 24
AvidBiotics Corp. 25
Cellceutix Corporation 26
Emergent BioSolutions Inc. 27
Evaxion Biotech ApS 28
F. Hoffmann-La Roche Ltd. 29
FOB Synthesis, Inc. 30
LegoChem Biosciences, Inc 31
Melinta Therapeutics, Inc 32
MicuRx Pharmaceuticals, Inc. 33
Nosopharm SAS 34
Omnia Molecular Ltd. 35
Pfizer Inc. 36
Phylogica Limited 37
Sarepta Therapeutics, Inc. 38
Sealife PHARMA GMBH 39
Shionogi & Co., Ltd. 40
Techulon, Inc. 41
Tetraphase Pharmaceuticals Inc. 42
Varinel, Inc. 43
Vaxdyn, S.L. 44
Acinetobacter Infections – Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Target 46
Assessment by Mechanism of Action 48
Assessment by Route of Administration 50
Assessment by Molecule Type 52
Drug Profiles 54
A-3APO - Drug Profile 54
AA-139 - Drug Profile 56
ACHN-975 Prodrug - Drug Profile 57
Acinetobacter vaccine - Drug Profile 58
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 59
Antisense Oligonucleotide for Acinetobacter baumannii Infections - Drug Profile 60
AR-401 - Drug Profile 61
AvR2-V10 - Drug Profile 62
Biologics for Acinetobacter Baumannii - Drug Profile 64
EV-035 - Drug Profile 65
Fab-001 - Drug Profile 67
FSI-1671 - Drug Profile 68
FSI-1686 - Drug Profile 69
GN-4474 - Drug Profile 70
LCB-010200 - Drug Profile 71
LCB-100200 - Drug Profile 72
MDN-0057 - Drug Profile 73
Monoclonal Antibodies for Gram-Negative Bacterial Infections - Drug Profile 75
MRX-V - Drug Profile 76
NOSO-95179 - Drug Profile 77
OM-011818 - Drug Profile 78
PMX-100 - Drug Profile 79
PMX-1091 - Drug Profile 80
PMX-1142 - Drug Profile 81
PMX-229 - Drug Profile 82
PMX-633 - Drug Profile 83
pneumonia vaccine - Drug Profile 84
RX-05 - Drug Profile 85
RXP-873 - Drug Profile 86
S-649266 - Drug Profile 87
SLP-0901 - Drug Profile 88
SLP-0905 - Drug Profile 89
Small Molecule for Acinetobacter baumannii Infections - Drug Profile 90
Small Molecule for Gram-Negative Nosocomial Infections - Drug Profile 91
Small Molecule to Inhibit Lipopolysaccharide for Nosocomial Infections - Drug Profile 92
Small Molecule to Target Bacterial Cell Membrane for Acinetobacter Infections - Drug Profile 93
Small Molecules for Acinetobacter baumannii Infection - Drug Profile 94
Small Molecules for Acinetobacter Infections - Drug Profile 95
Small Molecules for Bacterial Infections - Drug Profile 96
Small Molecules for Multi-Drug Resistant Bacterial Infections - Drug Profile 97
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections - Drug Profile 98
Small Molecules to Inhibit Aminoacyl-tRNA Synthetases for Bacterial Infections - Drug Profile 99
Small Molecules to Inhibit LpxC for Gram-Negative Bacterial Infections - Drug Profile 100
Small Molecules to Inhibit NDH-1 for Acinetobacter baumannii Infections - Drug Profile 101
Synthetic Peptide for Gram-Negative Bacterial Infections - Drug Profile 102
TP-6076 - Drug Profile 103
VAR-10100 - Drug Profile 104
VXD-001 - Drug Profile 105
VXD-003 - Drug Profile 106
Acinetobacter Infections – Recent Pipeline Updates 107
Acinetobacter Infections - Dormant Projects 112
Appendix 114
Methodology 114
Coverage 114
Secondary Research 114
Primary Research 114
Expert Panel Validation 114
Contact Us 114
Disclaimer 115
List of Tables
Number of Products under Development for Acinetobacter Infections, H1 2016 12
Number of Products under Development for Acinetobacter Infections – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Development by Companies, H1 2016 (Contd..1) 15
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Late Stage Development, H1 2016 17
Comparative Analysis by Early Stage Development, H1 2016 18
Products under Development by Companies, H1 2016 19
Products under Development by Companies, H1 2016 (Contd..1) 20
Products under Development by Companies, H1 2016 (Contd..2) 21
Products under Investigation by Universities/Institutes, H1 2016 22
Acinetobacter Infections – Pipeline by Achaogen Inc., H1 2016 23
Acinetobacter Infections – Pipeline by Adenium Biotech ApS, H1 2016 24
Acinetobacter Infections – Pipeline by AmpliPhi Biosciences Corporation, H1 2016 25
Acinetobacter Infections – Pipeline by Aridis Pharmaceuticals LLC, H1 2016 26
Acinetobacter Infections – Pipeline by AstraZeneca Plc, H1 2016 27
Acinetobacter Infections – Pipeline by AvidBiotics Corp., H1 2016 28
Acinetobacter Infections – Pipeline by Cellceutix Corporation, H1 2016 29
Acinetobacter Infections – Pipeline by Emergent BioSolutions Inc., H1 2016 30
Acinetobacter Infections – Pipeline by Evaxion Biotech ApS, H1 2016 31
Acinetobacter Infections – Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 32
Acinetobacter Infections – Pipeline by FOB Synthesis, Inc., H1 2016 33
Acinetobacter Infections – Pipeline by LegoChem Biosciences, Inc, H1 2016 34
Acinetobacter Infections – Pipeline by Melinta Therapeutics, Inc, H1 2016 35
Acinetobacter Infections – Pipeline by MicuRx Pharmaceuticals, Inc., H1 2016 36
Acinetobacter Infections – Pipeline by Nosopharm SAS, H1 2016 37
Acinetobacter Infections – Pipeline by Omnia Molecular Ltd., H1 2016 38
Acinetobacter Infections – Pipeline by Pfizer Inc., H1 2016 39
Acinetobacter Infections – Pipeline by Phylogica Limited, H1 2016 40
Acinetobacter Infections – Pipeline by Sarepta Therapeutics, Inc., H1 2016 41
Acinetobacter Infections – Pipeline by Sealife PHARMA GMBH, H1 2016 42
Acinetobacter Infections – Pipeline by Shionogi & Co., Ltd., H1 2016 43
Acinetobacter Infections – Pipeline by Techulon, Inc., H1 2016 44
Acinetobacter Infections – Pipeline by Tetraphase Pharmaceuticals Inc., H1 2016 45
Acinetobacter Infections – Pipeline by Varinel, Inc., H1 2016 46
Acinetobacter Infections – Pipeline by Vaxdyn, S.L., H1 2016 47
Assessment by Monotherapy Products, H1 2016 48
Number of Products by Stage and Target, H1 2016 50
Number of Products by Stage and Mechanism of Action, H1 2016 52
Number of Products by Stage and Route of Administration, H1 2016 54
Number of Products by Stage and Molecule Type, H1 2016 56
Acinetobacter Infections Therapeutics – Recent Pipeline Updates, H1 2016 110
Acinetobacter Infections – Dormant Projects, H1 2016 115
Acinetobacter Infections – Dormant Projects (Contd..1), H1 2016 116
List of Figures
Number of Products under Development for Acinetobacter Infections, H1 2016 12
Number of Products under Development for Acinetobacter Infections – Comparative Analysis, H1 2016 13
Number of Products under Development by Companies, H1 2016 14
Number of Products under Investigation by Universities/Institutes, H1 2016 16
Comparative Analysis by Early Stage Products, H1 2016 18
Assessment by Monotherapy Products, H1 2016 48
Number of Products by Top 10 Targets, H1 2016 49
Number of Products by Stage and Top 10 Targets, H1 2016 49
Number of Products by Top 10 Mechanism of Actions, H1 2016 51
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 51
Number of Products by Routes of Administration, H1 2016 53
Number of Products by Stage and Routes of Administration, H1 2016 53
Number of Products by Molecule Types, H1 2016 55
Number of Products by Stage and Molecule Types, H1 2016 55
